Q2 2026 saw revenues more than double year-over-year to $360.5 million, driven by Sephience's launch and a $50 million Novartis milestone. Net income reached $83.5 million, reversing a prior-year loss, while strong cash reserves support ongoing R&D and commercialization.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.